Aadi bioscience filed definitive proxy statement and schedules special meeting of stockholders for february 28, 2025

Proxy statement includes proposals on previously announced sale of fyarro and associated infrastructure to kaken for $100m, and $100m pipe financing to support in-licensing of adc portfolio aadi's board recommends stockholders vote "for" all proposals to support the company's business transformation company expects to close transactions in the first quarter of 2025, subject to stockholder approval and other closing conditions morristown, n.j. , feb. 5, 2025 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi) ("aadi" or the "company") announced it filed its definitive proxy statement with the u.s. securities and exchange commission (the "sec") on january 31, 2025, and today mailed its definitive proxy statement and a letter to stockholders, in connection with the company's upcoming special meeting of stockholders (the "special meeting") which is scheduled to be held on february 28, 2025.
AADI Ratings Summary
AADI Quant Ranking